Aspirin use in advanced uncontrolled glaucoma

Journal of Glaucoma

Volumn 13, Issue 5, 2004, Pages 365-370

  Bell, Nicholas P ^a,d   Orengo Nania, Silvia ^b   Pietz, Kenneth ^c   Gross, Ronald L ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CULLEN EYE INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Jones Pavilion   (United States)

Author keywords

Aspirin; Glaucoma; Visual fields

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; FEMALE; GLAUCOMA; HEALTH SURVEY; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SELF REPORT; STROKE; TRABECULECTOMY; VISUAL FIELD;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; JOINT DISEASES; MALE; RETROSPECTIVE STUDIES; TRABECULECTOMY; VISUAL FIELDS;

EID: 4644360233     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000133148.59933.50     Document Type: Review

References (25)

1. Spaeth GL. Definition and classification of glaucomas. In: Eid TM, Spaeth GL, eds. The Glaucomas: Concepts and Fundamentals. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:1.
2. Harris A, Ciulla TA, Kagemann L, et al. Vasoprotection as neuroprotection for the optic nerve. Eye. 2000;14:473-475.
3. Drance SM. Some factors in the production of low tension glaucoma. Br J Ophthalmol. 1972;56:229-242.
4. Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open angle glaucoma: The Egna-Neumarkt Study. Ophthalmology. 2000;107:1287-1293.
5. Weiss HJ, Aledort LM. Impaired platelet/connective-tissue reaction after aspirin ingestion. Lancet. 1967;2:495-497.
6. The Steering Committee of the Physicians' Health Study Research Group. Preliminary Report: Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1988;318:262-264.
7. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
8. Lewis HD, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983; 309:396-403.
9. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ. 1988;296:316-320.
10. The Canadian American Ticlopidine Study (CATS). The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;8649:1215-1220.
11. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002;300:729-735.
12. SAS/STAT User's Guide, version 8. Cary, NC: SAS Institute; 1999.
13. Box GEP, Hunter WG, Hunter JS. Statistics for Experimenters. New York: Wiley; 1978.
14. Early Treatment Diabetic Retinopathy Study Report No. 8. Effects of aspirin treatment on diabetic retinopathy. Ophthalmology. 1991;98:757-765.
15. Grilli M, Pizzi M, Memo M, et al. Neuroprotection by aspirin and sodium salicylate through blockade of NK-κB activation. Science. 1996;274: 1383-1385.
16. Riepe M, Kasischke K, Raupach A. Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke. 1997;28:2006-2011.
17. Nickells RW. Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. J Glaucoma. 1996;5:345-356.
18. Dreyer EB. The potential for neuroprotection in glaucoma. Ophthalmol Clin North Am. 1997;10:365-376.
19. Ritch R. Neuroprotection: is it already applicable to glaucoma therapy? Curr Opin Ophthalmol. 2000;11:78-84.
20. Linden C, Alm A. Acetysalicylic acid does not reduce the intraocular pressure variation in ocular hypertension or glaucoma. Exp Eye Res. 2000; 70:281-283.
21. Wilson MR, Hertzmark E, Walker AM, et al. A case-control study of risk factors in open angle glaucoma. Arch Ophthalmol. 1987;105:1066-1071.
22. Hayreh SS. The role of age and cardiovascular disease in glaucomatous optic neuropathy. Surv Ophthalmol. 1999;43(Suppl 1):S27-S42.
23. Chumbley LC, Brubaker RF. Low-tension glaucoma. Am J Ophthalmol. 1976;81:761-767.
24. Hart WM, Yablonski M, Kass MA, et al. Multivariate analysis of the risk of glaucomatous visual field loss. Arch Ophthalmol. 1979;97:1455-1458.
25. The Advanced Glaucoma Intervention Study Group (AGIS). 3. Baseline characteristics of black and white patients. Ophthalmology. 1998;105: 1137-1145.